Migraine attacks can be debilitating and can cause significant disability in patients. A few recently developed treatment strategies have focused on blocking certain molecular pathways implicated in migraine attacks. One such pathway is the calcitonin gene-related peptide (CGRP) pathway. The USFDA recently approved zavegepant, a novel nasal spray that inhibits CGRP and can be used for treating migraine with or without aura in adults.
This is the first CGRP-inhibitor nasal spray developed for this condition. The approval for this drug was granted based on two double-blind, randomized, placebo-controlled studies. Study details: 623 migraine patients in the treatment group and 646 in the placebo group 24% (147) of the patients in the treatment group experienced pain relief compared to 15% (96) in the placebo group. 40% of the patients in the test group reported relief from their prevalent…
